Last reviewed · How we verify
AG-73305
AG-73305 is a small molecule inhibitor of the PI3K/AKT/mTOR pathway.
AG-73305 is a small molecule inhibitor of the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors.
At a glance
| Generic name | AG-73305 |
|---|---|
| Sponsor | Allgenesis Biotherapeutics Inc. |
| Drug class | PI3K/mTOR inhibitor |
| Target | PI3K |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AG-73305 works by selectively inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.
Approved indications
- Advanced solid tumors
Common side effects
- Hyperglycemia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG-73305 CI brief — competitive landscape report
- AG-73305 updates RSS · CI watch RSS
- Allgenesis Biotherapeutics Inc. portfolio CI